Management of advanced stage ovarian cancer;Traitement initial des cancers épithéliaux de l'ovaire de stade avancé

Revue du Praticien

Volumn 54, Issue 16, 2004, Pages 1777-1786

  Morice, Philippe ^a   Camatte, Sophie ^a   Lhomme, Catherine ^a   Duvillard, Pierre ^a   Castaigne, Damienne ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM;

ADVANCED CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER STAGING; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT INDICATION;

CARCINOMA; COMBINED MODALITY THERAPY; DECISION TREES; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 8144220663     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Petterson F, Creasman WT, Shepard JH, Pecorelli S. International Federation of Gynecology and Oncology. Annual Report on the results of treatment in gynecological cancer. Stockholm (Sweden): Editorial Office, Radiumhemmet, 1995.
2. Schwartz PE, Zhenq W. Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis. Gynecol Oncol 2003; 90: 644-50.
3. Canis M, Rabischong B, Houlle C et al. Laparoscopic management of adnexal masses: a gold standard? Curr Opin Obstet Gynecol 2002; 14: 423-8.
4. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993; 11: 166-72.
5. Tumeurs épithéliales malignes de l'ovaire. standards, options, recommandations. Paris: John Libbey Eurotext, 1998.
6. Bristow RE, del Carmen MG, Pannu HK et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003; 90: 519-28.
7. Yoshida Y, Kurokawa T, Kawahara K et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 2004; 182: 227-33.
8. Jeffry L, Kerrou K, Camatte S et al. Peritoneal tuberculosis revealed by carcinomatosis on CT scan and uptake at FDG-PET. BJOG 2003; 110: 1129-31.
9. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987; 156: 263-4.
10. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-59.
11. Nquyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steren A. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 1993; 72: 3663-70.
12. Michel G, De laco P, Castaigne D et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 1997; 18: 9-15.
13. Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994; 53: 326-30.
14. Morice P, Joulie F, Camatte S et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 2003; 197: 198-205.
15. Van der Burg ME, Van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332: 629-34.
16. Brockbank EC, Ind TE, Barton DP et al. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer 2004; 14: 42-50.
17. Chi DS, Venkatraman ES, Massen V et al. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000; 77: 227-31.
18. Memarzadeh S, Lee SB, Berek JS et al. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2003; 13: 120-4.
19. Byrom J, Widjaja E, Redman CW et al. Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy? BJOG 2002; 109: 369-75.
20. Bristow RE, Duska LR, Lambrou NC et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000; 89: 1532-40.
21. Verqote IB, De Wever I, Decloedt J et al. Induction chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998; 71: 431-6.
22. Leblanc E, Querleu D, Fazel A et al. Decision laparoscopy in advanced ovarian cancer: a series of 102 cases. Int J Gynecol Cancer 2003; 13 (Suppl. 1): 43.
23. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn El, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999; 72: 93-9.
24. Mazzeo F, Berliere M, Kerger J et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 2003; 90: 163-9.
25. Morice P, Dubernard G, Rey A et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 2003; 197: 955-63.
26. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol. 2003; 88: 9-16.
27. Aabo K, Adams M, Adnitt P et al. Chemotherapy in advanced ovarian cancer: four systematic méta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998; 78: 1479-87.
28. Mc Guire WP, Hoskins W, Brady M et al. Cyclophosphamide and Cisplatin compared with Paclitaxel and Cisplatin in Patients with Stage III-IV Ovarian Cancer. N Engl J Med 1996; 334: 1-6.
29. Piccart MJ, Bertelsen K, Stuart G et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 2003; 13 (Suppl. 2): 144-8.
30. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000; 18: 106-15.
31. Berek JS, Bertelsen K, Du Bois A et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10 (Suppl. 1): 87-92.
32. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505-15.
33. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-5.